Measurement of co3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbon-tetrachloride-induced fibrosis

Biomarker Insights

Volumn 6, Issue , 2011, Pages 49-58

  Vassiliadis, Efstathios ^a,b   Larsen, Dorthe Vang ^a   Clausen, Rikke Elgaard ^a,c   Veidal, Sanne Skovgård ^a,b   Barascuk, Natasha ^a,b   Larsen, Lise ^a   Simonsen, Henrik ^a   Silvestre, Toni Segovia ^a   Hansen, Christina ^a   Overgaard, Trine ^a   Leeming, Diana Julie ^a   Karsdal, Morten A ^a,b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biomarkers; CCL4; CO3 610; Collagen; Extracellular matrix; Fibrosis; Liver

Indexed keywords

BIOLOGICAL MARKER; CARBON TETRACHLORIDE; COLLAGEN TYPE 3; GELATINASE B; PROTEIN CO3 610; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN DEGRADATION; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LIVER FIBROSIS; NONHUMAN; PROGNOSIS; QUANTITATIVE ANALYSIS; RAT; REMISSION; TISSUE SECTION;

ANIMALIA; RATTUS;

EID: 79958242395     PISSN: 11772719     EISSN: None     Source Type: Journal    
DOI: 10.4137/BMI.S6347     Document Type: Article

References (20)

1. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clinical Biochemistry. 2010;43:899-904.
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-18.
3. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem. 2000;275:35715-22.
4. Jarcuska P, Janicko M, Veseliny E, Jarcuska P, Skladany L. Circulating markers of liver fibrosis progression. Clin Chim Acta. 2010.
5. Atzori L, Poli G, Perra A. Hepatic stellate cell: a star cell in the liver. Int J Biochem Cell Biol. 2009;41:1639-42.
6. Knittel T, Kobold D, Saile B, Grundmann A, Neubauer K, Piscaglia F, et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology. 1999; 117:1205-21.
7. Novo E, di Bonzo LV, Cannito S, Colombatto S, Parola M. Hepatic myofibroblasts: a heterogeneous population of multifunctional cells in liver fibrogenesis. Int J Biochem Cell Biol. 2009;41:2089-93.
8. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134:1655-69.
9. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 2009;14:181-202.
10. Jensen LT. The aminoterminal propeptide of type III procolagen, Studies on physiology and pathophysiology. Danish Medical Bulletin. 1997;44(1): 70-8.
11. Ulrich D, Noah EM, Burchardt ER, Atkins D, Pallua N. Serum concentration of amino-terminal propeptide of type III procollagen (PIIINP) as a prognostic marker for skin fibrosis after scar correction in burned patients. Burns. 2002;28:766-71.
12. Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexateinduced liver fibrosis: a 10-year follow-up. Br J Dermatol. 2001;144: 100-3.
13. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004;99:1160-74.
14. Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol. 2005;3:553-80.
15. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010.
16. Ricard-Blum S, Chossegros P, Guerret S, Trepo C, Grimaud JA, Chevallier M. The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) is a potential serum marker of ongoing liver fibrosis. Clin Chim Acta. 1996;248: 187-95.
17. Stone PJ. Potential use of collagen and elastin degradation markers for monitoring liver fibrosis in schistosomiasis. Acta Trop. 2000;77:97-9.
18. Matsushima K, Bano M, Kidwell WR, Oppenheim JJ. Interleukin 1 increases collagen type IV production by murine mammary epithelial cells. J Immunol. 1985;134:904-9.
19. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-37.
20. Bonewald LF, Mundy GR. Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res. 1990;261-76.